R. Waltzman

发表

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

E. Venkatraman, D. Chi, P. Sabbatini, 2001, Gynecologic oncology.

Gerardo Capo, R. Waltzman, G. Capo, 2004, The journal of supportive oncology.

Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.

M. Fesen, Denise Williams, R. Waltzman, 2005, The oncologist.

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

S. Tavazoie, Shugaku Takeda, A. Ribas, 2018, Cell.

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

R. Larson, B. Druker, F. Guilhot, 2009, Haematologica.

Final hematologic results: Epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT)

Denise Williams, R. Waltzman, C. Croot, 2005 .

Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA).

Denise Williams, R. Waltzman, 2004 .

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

S. Verstovsek, R. Mesa, C. Harrison, 2011 .

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

T. Barbui, D. Niederwieser, L. Knoops, 2011 .

Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy

J. Rescigno, A. Berson, R. Waltzman, 2008, Diseases of the colon and rectum.

Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF).

T. Barbui, G. Barosi, A. Vannucchi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).

T. Barbui, G. Barosi, C. Harrison, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of chemotherapy-related anemia with erythropoietic agents: current approaches and new paradigms.

R. Waltzman, 2004, Seminars in hematology.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Francisco Cervantes, Giovanni Barosi, Viktoriya Stalbovskaya, 2012, The New England journal of medicine.

Phase II trial of paclitaxel in patients with soft-tissue sarcoma.

G. Schwartz, J. Bertino, E. Casper, 1998, Cancer investigation.

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

E. Venkatraman, L. Norton, R. Barakat, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 u in anemic patients with cancer receiving chemotherapy.

Denise Williams, P. Braly, R. Waltzman, 2005, Supportive cancer therapy.

A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease

R. Waltzman, 2004, Cancer.

Communicating about chemotherapy-induced anemia.

David Cella, Lillian Nail, Heidi Hamilton, 2007, The journal of supportive oncology.

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

H. Kantarjian, J. Cortes, R. Silver, 2009, Haematologica.

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

R. Larson, R. Clark, H. Kantarjian, 2012 .

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.

C. Piech, J. Fastenau, M. Duh, 2005, The oncologist.

RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).

S. Verstovsek, R. Huber, W. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Xiaolei Zhou, T. Barbui, L. Knoops, 2011 .

Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: Preliminary results of a comparative trial.

M. Fesen, R. Waltzman, G. Justice, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

S. Tavazoie, M. Postow, M. Mita, 2018 .

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

T. Barbui, L. Knoops, G. Barosi, 2012, The New England journal of medicine.

ymptom anagement and upportive Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μ g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy

M. Fesen, R. Waltzman, V. Charu, 2005 .